Casebia Therapeutics Begins Operations
The joint venture, created through a collaboration with Bayer and CRISPR Therapeutics, will be based in Cambridge, MA.
On August 19, 2016, Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started operations in Cambridge, MA. In December 2015, Bayer and CRISPR Therapeutics agreed to create a joint venture to discover, develop, and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. The two parties formally closed the transaction in the first quarter of 2016.
The joint venture has recently been incorporated as Casebia Therapeutics, a United Kingdom entity with its primary base of research operations in Cambridge. Casebia has access to gene-editing technology from CRISPR Therapeutics in specific disease areas, as well as access to protein engineering knowledge and relevant disease information through Bayer.
Source: Bayer
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
